13.3 Enterocutaneous Fistulas & Severe Malabsorption

13.3 Enterocutaneous Fistulas & Severe Malabsorption

Clinical Core: An enterocutaneous fistula (ECF) is an abnormal epithelialized communication connecting the lumen of the gastrointestinal tract to the cutaneous surface of the abdominal wall. The management of ECF demands strict adherence to the four-phase SNAP protocol: Sepsis control and resuscitation, Nutritional optimization and fluid/electrolyte repletion, Anatomical delineation via contrast imaging, and Planned definitive surgical reconstruction delayed for at least $3\text{ to } 6\text{ months}$. High-output ($> 500\text{ mL/day}$) and proximal fistulas mandate Parenteral Nutrition (PN), mL-for-mL balanced fluid replacement, and proactive zinc supplementation ($12\text{--}17\text{ mg}$ elemental zinc per liter of output). Enteral Nutrition (via fistuloclysis or distal feeding) is viable only when $\ge 75\text{ to } 100\text{ cm}$ ($\ge 4\text{--}5\text{ feet}$) of healthy, functional distal bowel remains. Clinicians evaluate spontaneous closure probability using the FRIEND mnemonic.

---

Enterocutaneous Fistula Classification & Pathophysiology

Over $75\%\text{ to } 85\%$ of all enterocutaneous fistulas arise as iatrogenic postoperative complications (e.g., inadvertent enterotomies during difficult adhesiolysis, anastomotic disruption, or erosion by synthetic mesh or foreign bodies). The remaining $15\%\text{ to } 25\%$ develop spontaneously from Crohn's disease, abdominal radiation, malignant infiltration, or severe diverticular abscesses.

+-----------------------------------------------------------------------------------------+
|                        ENTEROCUTANEOUS FISTULA CLASSIFICATION                           |
+-----------------------------------------------------------------------------------------+
| Parameter             | Category                        | Clinical Characteristics      |
| --------------------- | ------------------------------- | ----------------------------- |
| Anatomical Location   | Proximal (Stomach, Duodenum,    | High volume, enzyme-rich,     |
|                       | Jejunum)                        | severe skin digestion, high Na|
|                       | Distal (Ileum, Colon)           | Low/moderate volume, formed,  |
|                       |                                 | less caustic, high bacteria   |
| --------------------- | ------------------------------- | ----------------------------- |
| 24-Hour Output Volume | Low-Output                      | < 200 mL / 24 hours           |
|                       | Moderate-Output                 | 200 to 500 mL / 24 hours      |
|                       | High-Output                     | > 500 mL / 24 hours (often    |
|                       |                                 | reaches 1,000 to 3,000 mL/day)|
| --------------------- | ------------------------------- | ----------------------------- |
| Complexity            | Simple                          | Short/direct tract, no abscess,|
|                       |                                 | no obstruction, bowel intact  |
|                       | Complex (Enteroatmospheric, EAF)| Opens directly into open wound|
|                       |                                 | bed, frozen abdomen, 0% close |
+-----------------------------------------------------------------------------------------+

1. Anatomical Classification

• Proximal Fistulas (Stomach, Duodenum, Jejunum): Effluent contains high concentrations of electrolytes, hydrochloric acid, biliary salts, and pancreatic enzymes (trypsin, chymotrypsin, amylase, lipase). These active proteolytic and lipolytic enzymes induce rapid, severe chemical excoriation and autodigestion of surrounding abdominal skin. Large fluid losses ($1\text{ to } 3+\text{ L/day}$) rapidly induce hypovolemia, prerenal azotemia, and profound electrolyte depletion.
• Distal Fistulas (Ileum, Colon): Effluent is more formed, lower in volume, contains fewer active digestive enzymes, and poses less risk of caustic skin erosion. However, distal colonic fistulas carry high bacteriological burdens, increasing local wound infection risks.

2. Output Volume Classification

• Low-Output: $< 200\text{ mL/day}$. High probability of spontaneous closure; electrolyte derangements are uncommon.
• Moderate-Output: $200\text{ to } 500\text{ mL/day}$. Intermediate clinical course; requires careful monitoring.
• High-Output: $> 500\text{ mL/day}$ (often exceeding $1000\text{ to } 3000\text{ mL/day}$ in proximal jejunal fistulas). High risk of metabolic collapse, acute kidney injury, micronutrient dumping, and severe malnutrition. Spontaneous closure is rare.

3. Complexity & The Enteroatmospheric Fistula (EAF)

• Simple Fistula: Possesses a single, direct cutaneous tract, without an associated intra-abdominal fluid collection, without distal mechanical obstruction, and with bowel wall continuity preserved.
• Complex Fistula: Multiple branching tracts, associated active intra-abdominal abscesses, disrupted intestinal continuity, or an enteroatmospheric fistula.
• Enteroatmospheric Fistula (EAF): A catastrophic subclass occurring in the setting of an open abdomen (laparostomy). The enteric mucosal defect opens directly into the granulating peritoneal wound bed without overlying soft tissue or skin cover, creating an exposed, "floating" fistula in a "frozen abdomen." Spontaneous closure of an EAF is virtually $0\%$. Management requires specialized isolation appliances (e.g., negative-pressure wound therapy with barrier rings) to prevent enteric effluent from flooding the peritoneal wound, followed by delayed definitive reconstruction.

---

The "SNAP" Protocol for ECF Management

The clinical management of enterocutaneous fistulas requires a disciplined, chronological approach structured under the SNAP framework:

+-----------------------------------------------------------------------------------------+
|                        THE "SNAP" MANAGEMENT FRAMEWORK                                  |
+-----------------------------------------------------------------------------------------+
| Phase                 | Primary Objectives              | Critical Interventions        |
| --------------------- | ------------------------------- | ----------------------------- |
| S: Sepsis Control     | Eliminate mortality risk,       | Image-guided drainage of all  |
|    & Resuscitation    | restore perfusion and skin      | abscesses; targeted IV abx;   |
|    (Days 1 to 3)      | barrier integrity               | isotonic crystalloids; ostomy |
| --------------------- | ------------------------------- | ----------------------------- |
| N: Nutritional Support| Achieve positive nitrogen       | Protein 1.5-2.5 g/kg/d; PN for|
|    & Metabolic Care   | balance; correct zinc and       | high-output/proximal; EN via  |
|    (Weeks 1 to 6)     | electrolyte deficiencies        | fistuloclysis if >=75-100cm gut|
| --------------------- | ------------------------------- | ----------------------------- |
| A: Anatomy Delineation| Define tract, origin, and       | Water-soluble contrast fistulo|
|    (Weeks 2 to 8)     | rule out distal obstruction     | gram, CT enterography, MRE    |
| --------------------- | ------------------------------- | ----------------------------- |
| P: Plan Definitive    | Safe enterolysis, resection,    | Mandatory delay 3 to 6 months |
|    Surgery (Months 3+)| and re-anastomosis              | until adhesions soften        |
+-----------------------------------------------------------------------------------------+

Phase 1: S — Sepsis Control & Resuscitation (Days 1 to 3)

• Sepsis as the Primary Killer: Undiagnosed or poorly drained intra-abdominal abscesses account for $60\%\text{ to } 80\%$ of all fistula-related deaths. Sepsis drives relentless hypercatabolism, prevents fistula closure, and induces multi-organ failure.
• Imaging & Source Control: Immediate contrast-enhanced abdominopelvic CT to locate undrained fluid collections, followed by urgent image-guided percutaneous catheter drainage. Urgent operative exploration during this acute phase is avoided unless percutaneous access is impossible or generalized peritonitis is present.
• Resuscitation: Aggressive restoration of circulating blood volume using balanced isotonic crystalloids, targeted broad-spectrum antimicrobial therapy, and correction of prerenal azotemia.
• Wound & Skin Protection: Protection of the peristomal skin is vital to prevent full-thickness abdominal wall breakdown. Utilization of custom cut-to-fit ostomy appliances, hydrocolloid wafer barriers, and Negative Pressure Wound Therapy (NPWT) with specialized fistula exclusion techniques ("fistula-VAC").

Phase 2: N — Nutritional Support & Metabolic Care (Weeks 1 to 6)

• Hypercatabolism & Nitrogen Deficit: Fistula patients experience severe hypercatabolism; daily protein losses in fistula effluent combined with inflammatory proteolysis generate profound negative nitrogen balances (often $-15\text{ to } -25\text{ g/day}$ of nitrogen, equivalent to losing $100\text{ to } 150\text{ g/day}$ of dry lean tissue protein).
• Prescriptions:
  • Energy: $25\text{ to } 35\text{ kcal/kg/day}$ (preventing overfeeding);
  • Protein: $1.5\text{ to } 2.5\text{ g/kg/day}$ to achieve positive nitrogen balance and support tissue healing.
• Route Selection:
  • Total Parenteral Nutrition (TPN): The primary, mandatory nutritional modality for all patients with high-output proximal ECFs, complex enteroatmospheric fistulas, or discontinuous gastrointestinal tracts. Enteral feeding in proximal high-output ECFs dramatically stimulates pancreaticobiliary and enteric secretions, exacerbating fluid losses and preventing tract collapse.
  • Enteral Nutrition (EN): Indicated in low-output or distal ileal/colonic fistulas. In mid-gut or proximal fistulas, enteral nutrition can be delivered via fistuloclysis (intubating the distal efferent limb of the fistula with an enteral feeding tube) or feeding via a distal tube jejunostomy, provided there is at least $75\text{ to } 100\text{ cm}$ ($\ge 4\text{--}5\text{ feet}$) of healthy, non-obstructed, functional distal small bowel between the feeding site and the colon.

Phase 3: A — Anatomy Delineation (Weeks 2 to 8)

• Performed only after acute sepsis is completely resolved and the patient is hemodynamically and nutritionally stabilized.
• Diagnostic Modalities: Water-soluble contrast fistulogram under fluoroscopy, CT enterography, small bowel follow-through, or magnetic resonance enterography (MRE).
• Critical Findings to Document:
  1. Exact anatomical organ of origin (stomach, duodenum, jejunum, ileum, colon);
  2. Length and course of the fistula tract (tracts $> 2\text{ cm}$ favor closure; tracts $< 2\text{ cm}$ resist closure);
  3. Status of intestinal continuity (lateral defect vs. end disruption);
  4. Size of the enteric wall defect ($< 1\text{ cm}$ vs. $> 1\text{ cm}$);
  5. Presence or absence of distal mechanical obstruction;
  6. Presence of foreign bodies, active Crohn's disease, or malignancy.

Phase 4: P — Plan Definitive Surgery (Months 3 to 6+)

• The Mandatory Delay Rule: Definitive operative repair must be delayed for at least 3 to 6 months (and frequently 6 to 12 months in patients with an open abdomen, frozen abdomen, or multiple prior laparotomies).
• Surgical Biology of the "Hostile Abdomen": Between 1 week and 3 months following initial peritonitis or laparotomy, the peritoneal cavity undergoes an intense inflammatory response, forming dense, vascular, woody, fibrinous adhesions ("obliterative peritonitis"). Operative re-entry during this period inevitably causes catastrophic multiple enterotomies, severe hemorrhage, and recurrent fistulization (recurrence rates $> 30\%\text{ to } 50\%$).
• Adhesion Maturation: Delaying surgery allows dense vascular adhesions to mature, soften, and organize into pliable, avascular fibrous bands that can be safely divided by meticulous enterolysis.
• Operative Goal: Complete resection of the fistula tract and the affected bowel segment, with primary, tension-free end-to-end anastomotic reconstruction through healthy, well-vascularized tissue, followed by durable abdominal wall closure.

---

Fluid, Electrolyte & Zinc Replacement

High-volume enterocutaneous fistula losses represent an isotonic or slightly hypotonic fluid rich in essential electrolytes and trace elements.

+-----------------------------------------------------------------------------------------+
|                    TYPICAL ELECTROLYTE COMPOSITION OF GI SECRETIONS                     |
+-----------------------------------------------------------------------------------------+
| Source                | Sodium (mEq/L) | Potassium (mEq/L)| Chloride (mEq/L)| Bicarbonate |
| --------------------- | -------------- | ---------------- | --------------- | ----------- |
| Gastric               | 40 - 100       | 5 - 15           | 100 - 140       | 0           |
| Biliary / Pancreatic  | 130 - 150      | 5 - 10           | 40 - 80         | 30 - 90     |
| Small Bowel (Jejunal) | 100 - 140      | 5 - 15           | 90 - 120        | 20 - 40     |
| Small Bowel (Ileal)   | 80 - 120       | 5 - 15           | 60 - 90         | 20 - 40     |
+-----------------------------------------------------------------------------------------+

1. Replacement Protocol

• Milliliter-for-Milliliter Replacement: All measured fistula losses must be replaced mL-for-mL ($1:1$) every 4 to 8 hours using an appropriate intravenous crystalloid solution (e.g., Lactated Ringer's, Plasma-Lyte, or $0.45\%\text{ NaCl}$ with added sodium bicarbonate and potassium chloride) tailored to the measured electrolyte content of the drainage.
• Separation from Maintenance: Fistula replacement fluids must be administered as an independent infusion, separate from baseline maintenance IVF and Parenteral Nutrition.
• Acid-Base Management: High gastric losses produce hypokalemic, hypochloremic metabolic alkalosis (requiring $0.9\%\text{ NaCl}$ and $KCl$). High small bowel, biliary, or pancreatic losses waste vast amounts of bicarbonate, producing normal-anion-gap hyperchloremic metabolic acidosis (requiring replacement with sodium bicarbonate or balanced crystalloids with acetate/lactate buffers).

2. Zinc Homeostasis & Supplementation

Upper gastrointestinal secretions, bile, and pancreatic fluid are exceptionally rich in zinc. High-output fistula effluent drains $12\text{ to } 17\text{ mg}$ of elemental zinc per liter of output.

• Clinical Deficiency: Failure to replace zinc results in rapid, severe clinical deficiency manifested by an erythematous, scaling, vesicular periorificial and acral dermatitis (resembling acrodermatitis enteropathica), complete failure of wound healing, impaired epithelialization, intestinal mucosal blunting, diarrhea, alopecia, and cellular immune paralysis.
• Dosing Rule: For every liter of high-volume intestinal loss, clinicians must supplement $12\text{ to } 17\text{ mg}$ of elemental zinc daily (added to TPN or infused intravenously as trace elements) above standard maintenance requirements ($2.5\text{ to } 5.0\text{ mg/day}$).

---

Pharmacological Adjuncts in ECF Management

+-----------------------------------------------------------------------------------------+
|                        PHARMACOTHERAPY IN ENTEROCUTANEOUS FISTULA                       |
+-----------------------------------------------------------------------------------------+
| Drug Class            | Mechanism                       | Clinical Utility & Limits     |
| --------------------- | ------------------------------- | ----------------------------- |
| Proton Pump Inhibitors| Blocks gastric H+/K+ ATPase,    | Decreases proximal output by   |
| (e.g., Pantoprazole)  | suppressing acid secretion      | 1 to 2 L/day; protects skin   |
| --------------------- | ------------------------------- | ----------------------------- |
| Somatostatin Analogues| Inhibits GI endocrine/exocrine  | Reduces output volume by 50%; |
| (e.g., Octreotide)    | secretions; slows transit       | DOES NOT INCREASE CLOSURE RATE|
| --------------------- | ------------------------------- | ----------------------------- |
| Antimotility Agents   | Mu-opioid receptor agonist;     | Prolongs transit; useful in    |
| (e.g., Loperamide)    | blunts peristaltic contractions | distal/low-output fistulas     |
+-----------------------------------------------------------------------------------------+

1. Antisecretory Agents

• Proton Pump Inhibitors (PPIs, e.g., IV Pantoprazole $40\text{--}80\text{ mg/day}$): Profoundly suppresses gastric acid production, reducing fluid volume traversing gastroduodenal and proximal jejunal fistulas by $1\text{ to } 2\text{ L/day}$. This simplifies fluid balance, protects the abdominal wall from acid digestion, and reduces bicarbonate consumption.
• Somatostatin Analogues (Octreotide $100\text{--}200\text{ mcg}$ subcutaneous TID or continuous IV infusion): Inhibits gastrin, secretin, cholecystokinin, motilin, and pancreaticobiliary secretions, cutting fistula output by up to $50\%$ within $24\text{ to } 48\text{ hours}$.
  • Critical Evidence Caveat: Multiple randomized controlled trials and meta-analyses establish that while octreotide reliably decreases fistula volume (facilitating fluid management and pouching), it does NOT increase the ultimate rate of spontaneous fistula closure, nor does it shorten time to definitive surgery. If fistula volume does not decrease after $48\text{ to } 72\text{ hours}$, octreotide should be discontinued.

2. Antimotility Agents

• Loperamide ($2\text{ to } 4\text{ mg}$ dosed 30 minutes before meals and at bedtime, titrated up to $16\text{ mg/day}$): Acts on intestinal circular and longitudinal smooth muscle $\mu$-opioid receptors to slow intestinal transit. Useful in low-output or distal fistulas receiving enteral or oral intake to maximize mucosal contact time and water absorption.

---

Spontaneous Closure Predictors: The FRIEND Mnemonic

Spontaneous closure occurs in approximately $20\%\text{ to } 40\%$ of enterocutaneous fistulas under conservative medical and nutritional management. Clinicians utilize the classic FRIEND mnemonic to identify factors that prevent spontaneous closure:

+-----------------------------------------------------------------------------------------+
|                    FACTORS PREVENTING CLOSURE: THE "FRIEND" MNEMONIC                     |
+-----------------------------------------------------------------------------------------+
| Letter | Factor                  | Pathophysiological Mechanism                         |
| ------ | ----------------------- | ---------------------------------------------------- |
| F      | Foreign body            | Synthetic mesh, drain, or suture erodes tract lumen  |
| R      | Radiation               | Endarteritis obliterans, chronic ischemia & fibrosis  |
| I      | Infection / Inflammation| Undrained abscess, active sepsis, or Crohn's disease  |
| E      | Epithelialization       | Tract < 2 cm; mucocutaneous continuity forms bridge  |
| N      | Neoplasm                | Tumor cells invade tract, preventing tissue adhesion  |
| D      | Distal obstruction      | Intraluminal hydrostatic backpressure forces leakage |
+-----------------------------------------------------------------------------------------+

Factors Favoring Spontaneous Closure

1. Low Output: $< 200\text{ mL/day}$;
2. Long Tract: Length $> 2\text{ cm}$ (provides resistance to flow and permits granulation);
3. Small Bowel Defect: Enteric wall defect $< 1\text{ cm}$;
4. Anatomical Origin: Lateral duodenal, jejunal, or distal ileal fistulas with bowel continuity preserved;
5. Absence of FRIEND Criteria: No foreign body, radiation, sepsis, epithelialization, malignancy, or distal obstruction;
6. Nutritional Repletion: Normalizing visceral proteins (positive nitrogen balance).

Natural History & Timeline of Closure

Spontaneous closure, when achievable, occurs almost universally within 4 to 6 weeks of achieving sepsis control and optimal nutritional repletion. If a fistula continues to drain beyond 6 to 8 weeks under optimal conservative management, spontaneous closure is virtually impossible ($< 5\%$ probability). At that point, further conservative delays are futile, and management transitions to outpatient home nutritional rehabilitation while awaiting delayed definitive surgical reconstruction at 3 to 6 months.